logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Gilead Sciences, Inc.

USPTO Granted Patents = 946

% Expired Patents = 13.1



Trademarks = 126

Forward Citations = 20,413

Loading Chart...
Loading Chart...

1,011 inventors (with patents filed for the assignee):

goldMedal Richard L Mackman (92 out of 96 patents)

silverMedal William John Watkins (86 out of 94 patents)

bronzeMedal Jeff A Zablocki (75 out of 158 patents)

4.  Choung U Kim (67 out of 87 patents)

5.  John O Link (60 out of 99 patents)

6.  Hyung-Jung Pyun (59 out of 67 patents)

7.  Michael Graupe (56 out of 76 patents)

8.  Dustin S Siegel (56 out of 58 patents)

9.  James G Taylor (54 out of 96 patents)

10.  Aesop Cho (50 out of 58 patents)

11.  Scott E Lazerwith (50 out of 55 patents)

12.  Chandrasekar Venkataramani (48 out of 61 patents)

13.  Larry M Gold (48 out of 191 patents)

14.  Jennifer R Zhang (46 out of 48 patents)

15.  Jeromy J Cottell (44 out of 61 patents)


Core Competencies:
Capsid Inhibitors
HIV
PD-1 Inhibitors
Therapeutic Compositions
Viral Infections
Toll-Like Receptor Modulators
Antiviral Compounds
Modulating Compounds
Pharmaceutical Formulations
Nucleoside Analogues
MCL1 Inhibitors
IL-31 Modulators

946 patents:

1. 12723057 - ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME (2026-09-01),
2. D1140740 - Blister pack (2026-08-11),
3. 12678408 - Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine (2026-07-14),
4. D1131202 - Pharmaceutical package (2026-06-23),
5. 12661323 - Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine (2026-06-23),
6. 12655172 - Solid forms of a nucleoside analogue and uses thereof (2026-06-16),
7. 12648911 - Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine (2026-06-09),
8. 12636279 - Choline salt forms of an HIV capsid inhibitor (2026-05-26),
9. 12629338 - Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine (2026-05-19),
10. 12594267 - Capsid inhibitors for the treatment of HIV (2026-04-07),
11. 12594244 - Therapeutic compositions for treatment of human immunodeficiency virus (2026-04-07),
12. 12590089 - Processes for preparing toll-like receptor modulator compounds (2026-03-31),
13. 12590062 - PD-1/PD-L1 inhibitors (2026-03-31),
14. D1118367 - Blister pack (2026-03-17),
15. 12570662 - Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases (2026-03-10),
Company Overview
Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California, specializing in the development of innovative therapies for viral infections, particularly HIV. The company focuses on advanced treatment modalities, including capsid inhibitors and PD-1 inhibitors, to enhance patient outcomes. Gilead's research encompasses a range of therapeutic compositions and antiviral compounds, aiming to address unmet medical needs in the field of infectious diseases and improve the quality of life for patients globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Gilead Sciences, Inc. USPTO Patent Assignee Logo
946 Patents

#2 in Foster City, CA

#131 in California

#549 in US

#1,080 in the World

Foster City, CA (US)
Foster City, CA, United States of America

Gilead Sciences, Inc.

Forward Citations = 20,413

1,011 inventors:

goldMedal Richard L Mackman (92 out of 96 patents)

silverMedal William John Watkins (86 out of 94 patents)

bronzeMedal Jeff A Zablocki (75 out of 158 patents)

4.  Choung U Kim (67 out of 87 patents)

5.  John O Link (60 out of 99 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gilead Sciences, Inc.. Retrieved from https://idiyas.com/company/gilead-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…